Peter Attia's Medicine 3.0 inverts the old model of disease care. Medicine 1.0 and 2.0 wait for symptoms: chest pain → ECG → cardiology → stent. Medicine 3.0 prevents disease decades before symptoms appear. You don't wait for a heart attack. You check your bloodwork at 30, find preclinical markers of cardiovascular disease, and intervene. The cause of death in India for men over 40 is heart disease. The 10 longevity biomarkers below predict it, and most Indian doctors don't test them.
Longevity medicine tracks biomarkers that predict healthspan, not just disease absence. The key panels: metabolic (HbA1c, insulin, HOMA-IR), inflammatory (hsCRP, homocysteine), hormonal (testosterone, DHEA-S, IGF-1), and cellular (ApoB, Lp(a), vitamin D). Test quarterly to track biological aging.
| Marker | Optimal Range | Predicts | If Off-Target |
|---|---|---|---|
| ApoB | <70 mg/dL | Cardiovascular risk | Statin or ezetimibe; diet |
| Lp(a) | <50 mg/dL | Genetic CVD risk | Optimize other factors; lipoprotein apheresis if >200 |
| hs-CRP | <1 mg/L | Chronic inflammation, CVD | Exercise, anti-inflammatory diet, sleep |
| HbA1c | <5.3% | Diabetes, metabolic aging | Time-restricted eating, resistance training, GLP-1 |
| Fasting Insulin | <8 mIU/L | Insulin resistance, metabolic aging | Berberine, metformin, fasting, resistance training |
| Homocysteine | <10 µmol/L | Vascular and neurological aging | B vitamins (B6, B12, folate), TMG, betaine |
| Free Testosterone | 50–200 pg/mL (men); 1–5 pg/mL (women) | Muscle, bone, cognition, vitality | TRT if deficient; exercise, sleep, zinc for natural boost |
| DHEA-S | 200–400 µg/dL | Aging rate, resilience | DHEA supplementation 25–50mg daily; strength training |
| IGF-1 | 100–200 ng/mL | Longevity, growth capacity | Resistance training; avoid excessive IGF (cancer risk) |
| Vitamin D | 40–70 ng/mL | Immune, bone, cancer prevention | D3 supplementation 2,000–4,000 IU daily; sun exposure |
| Magnesium | >4.2 mg/dL (RBC) | Cardiovascular function, aging | Magnesium glycinate 300–400mg; RBC magnesium more accurate than serum |
Peter Attia, a physician and longevity researcher, coined the term Medicine 3.0 to describe a paradigm shift in how we approach health. The old model — Medicine 1.0 and 2.0 — is reactive: you get sick, you go to the doctor, you get treated. By the time you're diagnosed with heart disease, atherosclerosis has been building in your arteries for 20+ years.
Medicine 3.0 inverts this. It says: test early, find preclinical markers, intervene before pathology develops. Instead of waiting for symptoms, you measure biomarkers — the measurable biological indicators of disease risk — and act on them decades in advance.
The core concept: Most chronic diseases don't appear overnight. They build slowly, invisibly, in your bloodwork. Your arteries don't suddenly clog at 50. The process started at 25. Your metabolic health doesn't fail at 55. It's been declining since 35. Cancer, Alzheimer's, heart disease — all of these have preclinical markers that appear years or decades before symptoms.
In India, medicine remains largely 1.0 and 2.0. Physicians are trained in acute care — treat the heart attack, not the 20 years of preclinical disease that preceded it. This is why the 10 biomarkers below matter: they catch disease in its infancy, when intervention works.
You've heard of LDL cholesterol. It's the "bad" cholesterol, and doctors tell you to keep it low. But LDL-C misses the most important detail: it measures cholesterol content, not particle count.
Imagine two people: Person A has LDL-C of 100 mg/dL with 1,000 small, dense LDL particles. Person B has LDL-C of 110 mg/dL with 800 larger particles. By traditional LDL-C, Person B is "worse." But Person A has more particles driving atherosclerosis and is at higher cardiovascular risk.
ApoB measures the particle count. Every LDL particle has one ApoB molecule. So ApoB tells you the true number of atherogenic particles in your blood. Studies show ApoB is a stronger predictor of heart attack and stroke than LDL-C — especially in South Asian populations, which have genetic predisposition to high ApoB and cardiovascular disease.
Most Indian cardiologists still use LDL-C as the gold standard. But if you want to know your true cardiovascular risk, ApoB is the better test. arq. includes it in the 360° panel because it's more predictive.
Lipoprotein(a), or Lp(a), is a genetic variant of LDL cholesterol. About 75% of your Lp(a) level is determined by your parents' genetics — it's inherited. Unlike LDL cholesterol, which you can lower with statins and diet, Lp(a) barely budges.
High Lp(a) (>50 mg/dL) confers significant cardiovascular risk. It's roughly equivalent to a 30-point elevation in LDL cholesterol. If you have high Lp(a), you need aggressive management of everything else — ApoB, blood pressure, inflammation.
You only need to test Lp(a) once in your lifetime. If it's high, you know it. If it's low, you're protected genetically. arq. recommends testing it once, usually in your 20s or 30s, so you understand your genetic risk and can plan accordingly.
HbA1c is glucose "memory" — it reflects your average blood glucose over the past 2-3 months. Most doctors use it to diagnose diabetes (HbA1c >6.5%). But by then, damage is done. Your pancreas has been overworking for years.
Fasting insulin tells you how much insulin your body needs to control glucose. Normal fasting insulin is <12 mU/L. If it's elevated (>15), your cells are becoming insulin-resistant — you're pre-diabetic, metabolically.
Together, HbA1c and fasting insulin reveal metabolic health decades before diabetes develops. Many Indians have normal fasting glucose but elevated HbA1c and insulin. They're metabolically dysfunctional but haven't been diagnosed. Testing both reveals the truth.
hs-CRP (high-sensitivity C-reactive protein) measures systemic inflammation. Low-grade, chronic inflammation is a preclinical driver of cardiovascular disease, cancer, Alzheimer's, and metabolic disease. You can have perfectly normal cholesterol but high hs-CRP and still have cardiovascular risk.
Normal hs-CRP is <1 mg/L. Elevated (>3) signals chronic inflammatory burden. It could be from poor diet (processed foods, sugar), chronic stress, sleep deprivation, obesity, autoimmune disease, or chronic infection.
Lowering hs-CRP (through diet, exercise, sleep, stress management) reduces disease risk. Most Indian physicians don't test it because it's not part of standard acute care. But for longevity, it's essential.
Homocysteine is an amino acid produced by protein metabolism. High levels (>15 μmol/L) damage blood vessel walls and increase risk of cardiovascular disease, stroke, and cognitive decline. Homocysteine also predicts Alzheimer's risk — high levels correlate with brain atrophy and cognitive impairment in midlife.
Homocysteine is fixable: B vitamins (B6, B12, folate) lower it. Testing it identifies vascular risk you can address with supplementation before you develop heart disease or dementia.
DHEA-S (dehydroepiandrosterone sulfate) is produced by your adrenal glands. It peaks in your 20s and declines ~10% per decade. DHEA-S is a precursor to testosterone and estrogen, and it's associated with muscle mass, cognition, bone density, and immune function.
Low DHEA-S in midlife correlates with increased mortality risk, cognitive decline, and metabolic disease. It's a marker of adrenal aging. Testing it gives a baseline measure of how your body is aging at the biochemical level.
Total testosterone is the sum of bound and free testosterone. Free testosterone is the biologically active fraction. Low testosterone (total <300 ng/dL or free <5 pg/mL) correlates with loss of muscle mass, cognitive decline, mood changes, and metabolic disease.
arq. tests both because the full picture matters. You can have normal total testosterone but low free testosterone (especially if SHBG is high, which happens with obesity and insulin resistance). Free testosterone better predicts muscle mass and metabolic rate.
Vitamin D is produced by your skin when exposed to sunlight. Most Indians are deficient (levels <30 ng/mL). Deficiency is linked to weakened immunity, poor bone health, increased cancer risk, and metabolic disease.
Optimal Vitamin D for longevity is 40-60 ng/mL. Testing it identifies a deficiency that's easily fixable through supplementation or sun exposure.
ALT (alanine aminotransferase) and GGT (gamma-glutamyl transferase) are liver enzymes. Elevated levels signal fatty liver disease, metabolic dysfunction, or alcohol use. Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the #1 cause of cirrhosis in India, often silently.
Testing liver enzymes catches metabolic disease early. If ALT or GGT is elevated, your physician can investigate — it may signal insulin resistance, metabolic syndrome, or other conditions needing intervention.
Thyroid dysfunction affects metabolism, energy, temperature regulation, and cognition. Many doctors only test TSH and miss Free T3 and Free T4 abnormalities. A complete panel reveals the full thyroid picture — whether you have subclinical hypothyroidism (TSH elevated, but Free T4 normal), which is common and often undiagnosed.
Training: Indian medical education emphasizes acute care — treating symptomatic disease. Preventive testing in apparently healthy people is not standard practice.
Cost: Many tests (ApoB, Lp(a), hs-CRP, DHEA-S) aren't covered by government health systems. Private practitioners have traditionally focused on symptomatic patients who pay out-of-pocket for specific, problem-focused tests.
Culture: The phrase "why test if there's no symptom?" is common. Western longevity medicine (Peter Attia, function medicine) is still emerging in India. Most physicians don't know about Medicine 3.0.
Guideline lag: Indian medical guidelines are slower to adopt longevity markers compared to Western cardiology societies. Until guidelines officially recommend ApoB or Lp(a), mass testing won't happen.
arq.'s comprehensive bloodwork covers all 10 longevity biomarkers plus additional tests (complete CBC, metabolic panel, lipid panel, complete thyroid, hormones). Your physician reviews your full dataset, identifies preclinical risk, and builds a protocol to prevent disease.
Example scenario:
You're 38, feel fine. Your basic annual check shows normal glucose, normal cholesterol. But arq.'s 360° panel reveals: elevated ApoB (130 mg/dL), normal LDL-C (100 mg/dL), elevated hs-CRP (2.8), low Vitamin D (24 ng/mL), elevated fasting insulin (18 mU/L), low DHEA-S. You don't have heart disease. But you have 5+ preclinical markers of cardiovascular and metabolic risk.
Your physician doesn't wait for a heart attack. She prescribes: statins (to lower ApoB), Vitamin D supplementation, dietary intervention (lower refined carbs, increase fiber), exercise protocol, sleep optimization. In 3-6 months, markers improve. In 2 years, your cardiovascular risk has shifted dramatically.
This is Medicine 3.0 in practice.
Still waiting for symptoms? Your preclinical disease markers are in your bloodwork right now. Talk to an arq. physician to understand your longevity risk →
No AI chat. No templates. A specialist reads your panel against South Asian-calibrated ranges and writes the protocol on a 15–20 minute video consult — inside 7 days of your home draw.